ZA200510129B - Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle - Google Patents
Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle Download PDFInfo
- Publication number
- ZA200510129B ZA200510129B ZA200510129A ZA200510129A ZA200510129B ZA 200510129 B ZA200510129 B ZA 200510129B ZA 200510129 A ZA200510129 A ZA 200510129A ZA 200510129 A ZA200510129 A ZA 200510129A ZA 200510129 B ZA200510129 B ZA 200510129B
- Authority
- ZA
- South Africa
- Prior art keywords
- prodrug
- active drug
- eye
- active
- delivery
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 110
- 229940079593 drug Drugs 0.000 title claims description 106
- 229940002612 prodrug Drugs 0.000 title claims description 92
- 239000000651 prodrug Substances 0.000 title claims description 92
- 239000011859 microparticle Substances 0.000 title claims description 12
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 55
- 229960000565 tazarotene Drugs 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- IQIBKLWBVJPOQO-UHFFFAOYSA-N tazarotenic acid Chemical compound C1=C2C(C)(C)CCSC2=CC=C1C#CC1=CC=C(C(O)=O)C=N1 IQIBKLWBVJPOQO-UHFFFAOYSA-N 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 20
- 239000004005 microsphere Substances 0.000 claims description 17
- 210000001525 retina Anatomy 0.000 claims description 13
- 230000009471 action Effects 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 12
- 230000002207 retinal effect Effects 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000017442 Retinal disease Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 206010038848 Retinal detachment Diseases 0.000 claims description 8
- 210000000981 epithelium Anatomy 0.000 claims description 8
- 230000004264 retinal detachment Effects 0.000 claims description 8
- 230000002459 sustained effect Effects 0.000 claims description 8
- 208000002367 Retinal Perforations Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 210000003161 choroid Anatomy 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 5
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 4
- 229940123251 Platelet activating factor antagonist Drugs 0.000 claims description 4
- 206010038897 Retinal tear Diseases 0.000 claims description 4
- 230000003532 cataractogenesis Effects 0.000 claims description 4
- 201000011190 diabetic macular edema Diseases 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims description 4
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims description 4
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 3
- 210000001328 optic nerve Anatomy 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 150000001734 carboxylic acid salts Chemical class 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229940052760 dopamine agonists Drugs 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 102000003702 retinoic acid receptors Human genes 0.000 description 11
- 108090000064 retinoic acid receptors Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000001742 aqueous humor Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 6
- 210000004127 vitreous body Anatomy 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 208000029977 White Dot Syndromes Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 101100411708 Danio rerio rarga gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 208000027073 Stargardt disease Diseases 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- -1 poly(orthoester) Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000001982 uveitic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical compound OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000005598 Angioid Streaks Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 229940121840 Beta adrenoreceptor antagonist Drugs 0.000 description 1
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 208000019878 Eales disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 206010065119 Necrotising herpetic retinopathy Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010065373 Papillophlebitis Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 208000034247 Pattern dystrophy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 101150066717 Rara gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 description 1
- 206010038915 Retinitis viral Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000014286 Serpiginous choroiditis Diseases 0.000 description 1
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 description 1
- 208000017441 X-linked retinoschisis Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000019672 acute posterior multifocal placoid pigment epitheliopathy Diseases 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229940100609 all-trans-retinol Drugs 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000005845 branch retinal artery occlusion Diseases 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 208000006623 congenital stationary night blindness Diseases 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FPIPGXGPPPQFEQ-DPZDGVIMSA-N dihydroretinol Natural products CC(=CCO)C=CC=C(C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-DPZDGVIMSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 201000002165 neuroretinitis Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 208000008940 ocular tuberculosis Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 201000004849 posterior scleritis Diseases 0.000 description 1
- 201000002267 posterior uveal melanoma Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
- 208000034503 punctate inner choroidopathy Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 201000007714 retinoschisis Diseases 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003074 vasoproliferative effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/617,468 US20050009910A1 (en) | 2003-07-10 | 2003-07-10 | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200510129B true ZA200510129B (en) | 2007-02-28 |
Family
ID=33564972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200510129A ZA200510129B (en) | 2003-07-10 | 2005-12-13 | Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050009910A1 (fr) |
| EP (1) | EP1644047A2 (fr) |
| JP (1) | JP2007528851A (fr) |
| KR (1) | KR20060033008A (fr) |
| CN (1) | CN1882362A (fr) |
| AU (1) | AU2004260645B2 (fr) |
| BR (1) | BRPI0412496A (fr) |
| CA (1) | CA2531753A1 (fr) |
| IL (1) | IL172583A (fr) |
| MX (1) | MXPA06000408A (fr) |
| NO (1) | NO20056174L (fr) |
| NZ (2) | NZ544027A (fr) |
| PL (1) | PL380169A1 (fr) |
| RU (1) | RU2353393C2 (fr) |
| WO (1) | WO2005011741A2 (fr) |
| ZA (1) | ZA200510129B (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| JP2007513161A (ja) * | 2003-12-02 | 2007-05-24 | アラーガン、インコーポレイテッド | レチノイドによる光受容体の変性の予防および／または減少 |
| US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| JP2007529434A (ja) * | 2004-03-17 | 2007-10-25 | ラース マイケル ラーセン， | 視覚サイクルの阻害による網膜症の予防 |
| US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| AU2011211380B9 (en) * | 2004-04-30 | 2014-05-08 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitor implants |
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| WO2006043965A1 (fr) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Compositions ophtalmiques therapeutiques contenant des excipients sans danger pour la retine et leurs methodes |
| US8246949B2 (en) * | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
| PL1959925T3 (pl) * | 2005-12-02 | 2017-05-31 | (Osi) Eyetech, Inc. | Mikrocząstki o kontrolowanym uwalnianiu |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
| EP2319517B1 (fr) | 2006-06-01 | 2013-09-11 | Novagali Pharma S.A. | Utilisation des promédicaments pour une administration oculaire intrvitréenne |
| SG176097A1 (en) * | 2009-05-20 | 2011-12-29 | Ranbaxy Lab Ltd | Topical retinoid solutions |
| US10022348B2 (en) | 2009-05-20 | 2018-07-17 | Sun Pharmaceutical Industries Limited | Topical solution of isotretinoin |
| EP2538929A4 (fr) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire |
| WO2012039979A2 (fr) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Diffusion rapide de grosses nanoparticules polymères dans le cerveau de mammifères |
| JP5996544B2 (ja) | 2010-10-15 | 2016-09-21 | クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼球アクセス用装置 |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| EP2825206A1 (fr) | 2012-03-16 | 2015-01-21 | The Johns Hopkins University | Formulations à libération contrôlée pour l'administration d'inhibiteurs du hif-1 |
| CA2871745C (fr) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Nanoparticules pharmaceutiques presentant un transport muqueux ameliore |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| AU2013256130B2 (en) | 2012-05-03 | 2017-12-21 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6392209B2 (ja) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
| SG11201503637SA (en) | 2012-11-08 | 2015-06-29 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN105246529B (zh) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | 用于眼部注射的设备和方法 |
| EP3003454B1 (fr) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Appareil pour une administration de médicament à l'aide de multiples réservoirs |
| US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
| EP3099290A1 (fr) | 2014-01-28 | 2016-12-07 | Allergan, Inc. | Formulations topiques de rétinoïdes, et procédés d'utilisation |
| WO2015127368A1 (fr) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Formulations microbicides hypotoniques et leurs méthodes d'utilisation |
| CN106794321A (zh) | 2014-06-20 | 2017-05-31 | 科尼尔赛德生物医学公司 | 可变直径插管以及用于控制对药剂递送的插入深度的方法 |
| EP3250184A1 (fr) | 2015-01-27 | 2017-12-06 | The Johns Hopkins University | Formulations d'hydrogel hypotoniques pour le transport amélioré d'agents actifs au niveau de surfaces muqueuses |
| EP3340982B1 (fr) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Composés pour le traitement de troubles immunitaires et inflammatoires |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3413851B1 (fr) | 2016-02-10 | 2023-09-27 | Clearside Biomedical, Inc. | Emballage |
| WO2017192565A1 (fr) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique |
| WO2017197036A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
| EP3454856A4 (fr) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
| EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
| ES2902006T3 (es) | 2016-06-27 | 2022-03-24 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos médicos |
| CA3028751A1 (fr) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Agents antiproliferatifs a base de pyrimidine |
| CA3072847A1 (fr) | 2016-08-12 | 2018-02-15 | Clearside Biomedical, Inc. | Dispositifs et procedes de reglage de la profondeur d'insertion d'une aiguille pour administration de medicament |
| WO2019009265A1 (fr) * | 2017-07-04 | 2019-01-10 | 第一三共株式会社 | Médicament contre une maladie dégénérative de la rétine associée à une dégénérescence des photorécepteurs |
| WO2019191112A1 (fr) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Liants de céréblon pour la dégradation d'ikaros |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| EP3866773A4 (fr) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5275820A (en) * | 1990-12-27 | 1994-01-04 | Allergan, Inc. | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles |
| US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| WO1995003009A1 (fr) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Methode de traitement de la degenerescence maculaire |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| AU704591B2 (en) * | 1994-04-04 | 1999-04-29 | William R. Freeman | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
| ES2258495T3 (es) * | 1994-04-08 | 2006-09-01 | Qlt Usa, Inc. | Composiciones de administracion liquida de farmacos. |
| US5824685A (en) * | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| US6277413B1 (en) * | 1998-07-17 | 2001-08-21 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| US6017938A (en) * | 1998-07-28 | 2000-01-25 | Bershad; Susan | Short contact treatment for acne |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| AU6815901A (en) * | 2000-06-02 | 2001-12-17 | Zycos Inc | Delivery systems for bioactive agents |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| JP4061015B2 (ja) * | 2000-10-30 | 2008-03-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レチノイン酸レセプターアゴニスト作用を有する薬剤含有組成物 |
| US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| JP2004536799A (ja) * | 2001-04-26 | 2004-12-09 | コントロール・デリバリー・システムズ・インコーポレイテッド | コドラッグを含有する持続的放出用ドラッグデリバリーシステム |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7381426B2 (en) * | 2002-01-24 | 2008-06-03 | Southwest Research Institute | Targeted delivery of bioactive factors to the systemic skeleton |
| EP1558264A4 (fr) * | 2002-09-29 | 2009-06-17 | Surmodics Inc | Procede d'administration sub-retinienne d'agents therapeutiques comprenant des steroides, procede servant a concentrer une action pharmacodynamique au niveau de la choroide et de la retine et procedes associes servant a traiter et/ou a prevenir des maladies retiniennes |
-
2003
- 2003-07-10 US US10/617,468 patent/US20050009910A1/en not_active Abandoned
-
2004
- 2004-07-07 CN CNA2004800195540A patent/CN1882362A/zh active Pending
- 2004-07-07 JP JP2006518912A patent/JP2007528851A/ja active Pending
- 2004-07-07 AU AU2004260645A patent/AU2004260645B2/en not_active Ceased
- 2004-07-07 CA CA002531753A patent/CA2531753A1/fr not_active Abandoned
- 2004-07-07 MX MXPA06000408A patent/MXPA06000408A/es unknown
- 2004-07-07 WO PCT/US2004/021938 patent/WO2005011741A2/fr active Application Filing
- 2004-07-07 PL PL380169A patent/PL380169A1/pl not_active Application Discontinuation
- 2004-07-07 EP EP04777796A patent/EP1644047A2/fr not_active Withdrawn
- 2004-07-07 RU RU2006104983/14A patent/RU2353393C2/ru not_active IP Right Cessation
- 2004-07-07 NZ NZ544027A patent/NZ544027A/en not_active IP Right Cessation
- 2004-07-07 KR KR1020067000591A patent/KR20060033008A/ko active Search and Examination
- 2004-07-07 BR BRPI0412496-0A patent/BRPI0412496A/pt not_active IP Right Cessation
- 2004-07-07 NZ NZ582376A patent/NZ582376A/en not_active IP Right Cessation
-
2005
- 2005-12-13 ZA ZA200510129A patent/ZA200510129B/en unknown
- 2005-12-14 IL IL172583A patent/IL172583A/en not_active IP Right Cessation
- 2005-12-23 NO NO20056174A patent/NO20056174L/no not_active Application Discontinuation
-
2012
- 2012-02-29 US US13/407,906 patent/US20120157499A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004260645A1 (en) | 2005-02-10 |
| US20050009910A1 (en) | 2005-01-13 |
| IL172583A (en) | 2011-02-28 |
| EP1644047A2 (fr) | 2006-04-12 |
| MXPA06000408A (es) | 2006-03-17 |
| US20120157499A1 (en) | 2012-06-21 |
| NO20056174L (no) | 2006-01-25 |
| NZ582376A (en) | 2012-02-24 |
| NZ544027A (en) | 2010-07-30 |
| AU2004260645B2 (en) | 2010-03-11 |
| IL172583A0 (en) | 2006-04-10 |
| WO2005011741A3 (fr) | 2005-04-14 |
| KR20060033008A (ko) | 2006-04-18 |
| PL380169A1 (pl) | 2007-01-08 |
| WO2005011741A2 (fr) | 2005-02-10 |
| CN1882362A (zh) | 2006-12-20 |
| JP2007528851A (ja) | 2007-10-18 |
| RU2006104983A (ru) | 2006-06-27 |
| RU2353393C2 (ru) | 2009-04-27 |
| BRPI0412496A (pt) | 2006-09-19 |
| CA2531753A1 (fr) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004260645B2 (en) | Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle | |
| US9572859B2 (en) | Compositions and methods for localized therapy of the eye | |
| EP2964194B1 (fr) | Hydrogel thermosensible contenant des microparticules polymères pour l'administration de médicament oculaire non invasive | |
| ES2435398T3 (es) | Tratamiento de retinopatía exudativa con mineralocorticoides | |
| US20110076318A1 (en) | Retinoid-containing sustained release intraocular implants and related matters | |
| US8877229B2 (en) | Controlled release microparticles | |
| JP2007535563A5 (ja) | レチノイド含有徐放性眼内薬剤送達システム、ならびに関連する製造法 | |
| BRPI0915981A2 (pt) | método para tratar a degeneração macular atrófica relacionada à idade | |
| Mezei et al. | Liposomes and nanoparticles as ocular drug delivery systems | |
| Guidetti et al. | Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers | |
| Shah et al. | Nanoparticulate transscleral ocular drug delivery | |
| WO2014153384A1 (fr) | Formulations de corticostéroïde pour le traitement de douleur articulaire et leurs procédés d'utilisation | |
| AU2004296748B2 (en) | Prevention and/or reduction of photoreceptor degeneration with retinoids | |
| JP2010510292A (ja) | 抗痙攣医薬組成物 | |
| US20220160694A1 (en) | Plasma kallikrein inhibitors and methods of use thereof in ocular disorders | |
| TW202227042A (zh) | 雙重鎮痛／消炎組合物、組合及其使用方法 | |
| Urtti | 2 Kinetic aspects in the design of prolonged action ocular drug delivery systems | |
| WO2016061378A1 (fr) | Systèmes et méthodes basés sur l'iac pour le traitement local de l'uvéite | |
| MXPA06006024A (es) | Prevencion y/o reduccion, con retinoides de la degeneracion de fotorreceptores |